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(UC) remains a major challenge. Past research has implicated the immune system in tumor
surveillance of both malignancies, leading to the application of immunotherapy agents for
both cancers. Among them, the most promising agents are the checkpoint blockade drugs, such
as antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4),
programmed death receptor 1 (PD-1), and PD-1 ligand (PD-L1). In normal physiology, these
immune checkpoints act as inhibitory signals to fine-tune the duration and strength of immune
reactions, which is pivotal for maintaining self-tolerance. However, tumor cells also utilize
immune checkpoint pathways to evade anti-tumor immune response, leading to disease
progression and metastasis. Thus, there has been intense preclinical and clinical effort focused
on the application of checkpoint inhibitors in metastatic RCC and UC. To date, nivolumab
(anti-PD-1) and atezolizumab (anti-PD-L1) have been approved for the treatment of metastatic
RCC and UC, respectively. Despite these successes, challenges remain in how to furtheruke.edu (T. Zhang).
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Immune checkpoint inhibitor approaches for metastatic genitourinary cancers 269improve response rates to immunotherapy and how to select patients that will benefit
from this approach. In this report, we review existing data and research on immunotherapy
in metastatic RCC and UC.
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An estimated 338,000 new cases of renal cell carcinoma (RCC)
and 429,000 new cases of urothelial carcinoma (UC) were
diagnosed worldwide in 2012 [1]. Of all genitourinary cancers,
RCC has the highest mortality rate, at 30% per year [1,2].
Meanwhile, UC, the vast majority of which is urothelial can-
cer of the bladder (UBC), is the 9th most common cancer with
165,000 related deaths worldwide in 2012 [1]. For patients
with advanced RCC or UC, the median survival duration from
time of diagnosis is less than 2 years. The poor prognosis of
RCC and UC may be attributed to the lack of major advances
for the treatment of patients with metastatic disease [3,4].
The immune system has long been theorized to play an
intrinsic role in tumor surveillance of RCC. Spontaneous
tumor regressions, prolonged stable disease intervals and
delayed relapse rates have been detected in patients with
RCC after cytoreductive nephrectomies [5]. Many groups
have described the presence of tumor infiltration with
various immune cells, including T-cells, natural killer (NK)
cells, dendritic cells (DCs) and macrophages. These obser-
vations have promoted the development of immunotherapy
of RCC over the past few decades [6]. In 1992, high dose
interleukin-2 (IL-2) was approved by United States Food and
Drug Administration (U.S. FDA) to treat patients with meta-
static RCC (mRCC). However, the clinical benefits were
limited since durable complete responses occurred in only a
rare subset of patients. Furthermore, high dose IL-2 resulted
in substantial treatment-related toxicities, which required
administration with intensive supportive care in an inpatient
setting [7]. In order to reduce toxicity and enhance efficacy,
a series of phase II and phase III trials were conducted to
compare high-dose IL-2 alone with low-dose outpatient ad-
ministrations or combination of low-dose IL-2 and interferon-
alpha (IFN-a) in patients with mRCC. Unfortunately, these
attempts of dose reduction schedules or combination cyto-
kine programs failed to improve the survival benefits and led
to more severe toxicities [7e11]. Overall, the previous
mainstays of cytokine immunotherapies such as high dose IL-2
and IFN-a only delivered limited objective responses in 10%e
15% of patients with mRCC, with an overall median survival
time of about 12 months [12]. Until November 2015, there
was no optimal immunotherapy for patients with mRCC.
The treatment strategy of metastatic UC (mUC) has
depended heavily on systematic chemotherapies, with
cisplatin-containing regimens having the most success. Far
less attention has been drawn to this lethal disease [13]. The
local susceptibility of bladder cancer to the immune system
has been confirmed for more than 2 decades [14,15]. The
presence of tumor-infiltrating lymphocytes (TILs) and
secreted cytokines play a critical role in the host antitumorresponse, and also is the basis of using the Bacillus
CalmetteeGuerin (BCG) vaccine to treat patients with su-
perficial bladder cancer [16]. However, the applications of
immunotherapy have presented a great challenge in muscle-
invasive bladder cancer (MIBC) and metastatic UBC.
In this review, we discuss the rationale of novel
immunotherapeutic strategies for mRCC and mUC, recent
advances of immune checkpoint inhibitors in these two
lethal diseases, and other potential targets in the future.
2. Brief rationale of novel immunotherapy
T-cell mediated immunity is a complex process with mul-
tiple sequential steps, and each step is regulated by a
delicate balance of stimulatory and inhibitory signals
(Fig. 1). Antigen-specific naı¨ve T-cells are activated through
signal one, between the interaction of the T-cell receptor
(TCR) and the major histocompatibility complex (MHC) on
tumor cells, and signal two, between the CD28 receptor on
T-cells and the B7 receptor on tumor cells. The B7 receptor
can potentially also bind the cytotoxic T-lymphocyte-asso-
ciated antigen 4 (CTLA-4) receptor on T-cells, which then
suppresses T-cells and leads to immune tolerance or
anergy. Another major inhibitor pathway signals from the
interaction of programmed cell death 1 (PD-1) on T-cells
and its ligand, PD-L1 on tumor cells. These immune
checkpoint pathways counterbalance the stimulatory
pathways to stop an immune response. In normal tissues,
these signals act as the “brake” to fine-tune the duration
and strength of physiologic immune reactions and to avoid
collateral damage caused by an overactive host immune
response. Comparatively, tumor cells may overexpress im-
mune checkpoint molecules to escape from tumor-specific
T-cell immunity in the cancer microenvironment; this
tumor escape can lead to subsequent progression and
metastasis. Thus, insufficient T-cell activation caused by
the redundant negative regulation may partially explain
some resistance to antitumor treatments and the poor
response to conventional immunotherapy, such as cytokine
treatments. Recently, increasing attention has been drawn
to “loosen the brake” by blocking these CTLA-4 and PD-1
inhibitory pathways to restore host immune response
against tumors [17e19].
3. Novel immunotherapy approaches
3.1. CTLA-4
During the priming phase of T-cell mediated immunity, one
of the best characterized co-stimulatory molecules is the
Figure 1 Mechanism of antitumor immunity and immune checkpoint inhibitors. Tumor surveillance is mediated through a series
of activating and inhibitory signals. T-cell activation occurs through signal 1 (between the TCR and the MHC complex) and signal 2
(between CD28 and the B7 receptor on APCs). The CTLA-4 receptor on T-cells competes with CD28 for B7 ligands to terminate T-cell
activation in the priming phase. PD-1 is expressed on effector T-cells and binds to PD-L1 on tumor cells to exhaust T-cells and
suppress its antitumor effect. Blockade of CTLA-4 (anti-CTLA-4), PD-1 (anti-PD-1) or PD-L1 (anti-PD-L1, not included in this figure)
restores host immune function and induces antitumor activity. Reproduced with permission from Raman R and Vaena D. Biomed Res
Int 2015; 2015:367354 [5], copyright ª2015. TCR, T-cell receptor; MHC, major histocompatibility complex; APCs, antigen-
presenting cells; CTLA-4, cytotoxic T-lymphocyte antigen-4; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.
Figure from Immunotherapy in metastatic renal cell carcinoma: a comprehensive review [5].
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antigen presenting cells (APCs) and T-cells. CTLA-4 is
exclusively expressed on T-cells and was initially thought to
be a co-stimulatory molecule similar to CD28, but further
studies proved its inhibitory effect, dampening the early
activity of naı¨ve and memory T-cells [20,21]. APCs present
two subtypes of the B7 protein, B7.1 (CD80) and B7.2
(CD86), which can bind either CD28 or CTLA-4. Once a
cognate antigen is recognized by the TCR, CD28 signaling
strongly augments TCR signaling to activate T-cells. On the
other hand, CTLA-4 may outcompete CD28 by binding B7.1
and B7.2 with a much higher affinity in order to terminate
T-cell activation at an early stage [22]. However, the en-
tirety of other downstream effects of the CTLA-4 pathway
is still under investigation.
3.1.1. Anti-CTLA-4 in mRCC
The inhibitory role of CTLA-4 has been elucidated using
genetically engineered mice which are deficient in CTLA-4
[23]. Thesemice develop lymphoproliferative disorders with
multi-organ lymphocytic infiltration and tissue destruction.
Preclinical models of tumor-bearing mice also showed tumor
shrinkage related to antitumor immunity via CTLA-4
blockade [24]. These promising preclinical results encour-
aged the development of anti-CTLA-4 therapy for cancer
patients. The first and most clinically studied anti-CTLA-4
strategy to date is ipilimumab (also known as MDX-010,
Yervoy), a monoclonal antibody targeting CTLA-4 that is
FDA approved for treatment of unresectable or metastatic
melanoma [25,26]. For patients with mRCC, a single institu-
tion phase II trial showed that only one of 21 patients had a
partial response (PR) with low-dose ipilimumab (3 mg/kgfollowed by 1 mg/kg every 3 weeks), and five of 40 patients
had PRs in the high-dose cohort (3 mg/kg every 3 weeks),
including two responses from patients had failed high dose
IL-2 therapy [27]. Intriguingly, the response rate was 30% in
patients who developed immune-related adverse events
(irAEs) but 0% in patients free of autoimmune toxicities
(pZ 0.0007), indicating that tumor regression was strikingly
associated with autoimmune events. This effect may be
explained by the autoimmunity induced in a variety of other
target tissues in addition to tumor tissues.
Another CTLA-4 antibody that has been studied in pa-
tients with mRCC is tremelimumab (CP-675206). A phase I
trial (NCT00372853) enrolled 28 adult patients with mRCC
who had previously received systemic treatments. In a 3 þ 3
dose escalation scheme, they were treated with intravenous
tremelimumab (6 mg/kg, 10 mg/kg or 15 mg/kg) every 12
weeks combined with oral sunitinib (50 mg daily for 4 weeks
with 2 weeks off or 37.5 mg daily as a continuous dose). Dose
limited toxicities (DLT) were detected in two of five patients
receiving tremelimumab 6 mg/kg and sunitinib 50 mg, and in
three of six patients treated with tremelimumab 15 mg/kg
and continuous sunitinib at 37.5 mg. In addition, one of
seven patients treated with tremelimumab 10 mg/kg and
continuous sunitinib 37.5 mg suffered a sudden death, and
three DLT events occurred in an expansion cohort of seven
additional patients at the same dose level [28]. Although PRs
were detected in 43% of patients, the toxicity was signifi-
cantly with the combination compared with historical data
of sunitinib alone, especially the high incidence of rapid
onset renal failure [29]. Thus, further combination in-
vestigations may move back to the preclinical setting to
evaluate the increased renal toxicity.
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Active investigation of CTLA-4 as an immunotherapy target
is also ongoing in the treatment of mUC. Given the standard
use of systemic neoadjuvant chemotherapy prior to cys-
tectomy, a phase II study detected the safety and immune
effects of neoadjuvant ipilimumab for localized UBC.
Twelve patients were enrolled to receive ipilimumab at an
escalating dose between 3 and 10 mg/kg for two cycles.
The results showed a tolerable safety profile in the pre-
operative setting. Furthermore, an increased number of
CD4þ T lymphocytes expressing ICOS (inducible cos-
timulatory; CD4þICOShi T-cells) was also detected in both
tumor tissue and the peripheral blood after anti-CTLA-4
treatment. CD4þICOShi T-cells were found to produce IFN-g
and recognize the tumor antigen NY-ESO-1, resulting in
the elevated ratio of effector T-cells to regulatory T-cells
and enhanced tumor-related immune responses. There-
fore, it might be a potential biomarker to monitor the
clinical outcome of ipilimumab [30,31]. Based on the
considerable activity of ipilimumab, an ongoing phase II
trial (NCT01524991) was conducted to evaluate ipilimumab
combined with gemcitabine and cisplatin as first-line
treatment of patients with mUC. Furthermore, another
phase 1b/2 trial (NCT02205333) is underway to deliver an
OX-40 agonist (MEDI6469) alone or combined with either
tremelimumab, durvalumab (anti-PD-L1 monoclonal anti-
body; MEDI4736), or rituximab (anti-CD20 monoclonal
antibody) to treat a variety of advanced solid tumors or
aggressive B-cell lymphomas [32].
3.2. PD-1
PD-1 is a pivotal immune checkpoint receptor on the sur-
face of activated T-cells, which can be engaged by PD-1
ligands, including PD-L1 (i.e., B7-H1 or CD274) and PD-L2
(i.e., B7-DC or CD273) [33,34]. In contrast to the CTLA-4
receptor, the main role of PD-1 is to limit T-cell activity
at the time of an inflammatory response to infection rather
than regulate T-cell activation. More specifically, the
interaction between PD-1 and its ligands may inhibit T-cell
proliferation, cytokine production, and cytotoxic function.
After exposure to INF-g produced by activated T-cells, PD-
L1 can be highly expressed by diverse subsets of cells, such
as T-cells, epithelial cells and cancer cells [35]. Thus, PD-1
signaling may translate into an immune resistance mecha-
nism in the tumor microenvironment, which may be
explained as a consequence of either constitutive activa-
tion of an oncogenic pathway, or infiltrating immune cell
production of interferons [36]. Preclinical studies have
demonstrated that blockade of the interaction between
PD-1 and PD-L1 can restore host immune function and
induce antitumor activity.
3.2.1. PD-1 inhibitors in mRCC
Nivolumab (i.e., Opdivo, ONO-4538, BMS-936558 or
MDX1106), the most researched PD-1 blocking antibody, is
the only therapeutic checkpoint inhibitor with U.S. FDA
approval to treat mRCC after disease progression with anti-
angiogenic agents. Nivolumab has also been approved to
treat patients with metastatic melanoma and non-small
cell lung cancer.A phase I trial (NCT00441337) of single-agent nivolumab
primarily demonstrated its safety and efficacy in 39 pa-
tients with various types of advanced solid tumors,
including one patient with mRCC that had a PR in the study
[37]. This was the first time that a PD-1 inhibitor was
studied in a clinical trial form RCC. Subsequently, another
phase I trial with a dose expansion phase in mRCC
(NCT0730639) enrolled more heavily pretreated patients to
receive nivolumab. In 34 patients with mRCC, 10 (29%)
obtained an objective response (OR) with a median dura-
tion of 12.9 months. Meanwhile, stable disease (SD) was
achieved in nine patients (27%) and lasted for at least 24
weeks. Subjects developed predominantly grade 1 or 2 AEs
(e.g., rash, hypothyroidism, hepatitis, nausea, adrenal
insufficiency, diarrhea and vitiligo). Grade 3 or 4 treatment-
related toxicities occurred in six of 34 patients (18%) and
were all manageable [38,39]. In addition, neither of these
two phase I studies reached the maximum tolerated dose.
All of these results indicate that nivolumab is well tolerated
and can deliver a durable antitumor activity in a subset of
patients with mRCC. Also, it is feasible to administrate
nivolumab in an outpatient setting.
A subsequent phase II study (NCT01354431) further
added to a growing body of evidence supporting the effi-
cacy and safety of nivolumab. One hundred and sixty-eight
mRCC patients previously treated with at least one vascular
endothelial growth factor receptor (VEGFR) inhibiting agent
were randomized to receive intravenous nivolumab at three
dose levels (0.3 mg/kg, 2 mg/kg or 10 mg/kg every 3
weeks). A doseeresponse relationship was not observed for
progression free survival (PFS), and there was no distinction
of response rates among the three dose groups. Although
PFS was not impressive, prolonged overall survival (OS) was
noted in 2 and 10 mg/kg groups compared with that in
0.3 mg/kg group (25.5 and 24.7 months, respectively, vs.
18.2 months) [40].
Based on these promising results, a pivotal phase III trial
(NCT01668784) was conducted to compare nivolumab with
everolimus, an approved mTOR inhibitor for patients with
mRCC that have failed previous anti-angiogenic treatment.
In total, 821 previously treated patients with advanced RCC
were assigned in a 1:1 ratio to have either nivolumab
3 mg/kg intravenous every 2 weeks or everolimus 10 mg by
mouth daily. Although the median PFS was almost the same
in the two groups (4.6 months with nivolumab vs. 4.4
months with everolimus), the median OS with nivolumab
was significantly longer than that with everolimus (25.0
months vs. 19.6 months), and the hazard ratio for any death
was 0.73 (nivolumab vs. everolimus, 98.5%CI, 0.57e0.93;
p Z 0.002). Meanwhile, the objective response rate (ORR)
in nivolumab group was 25% compared with only 5% in the
everolimus group (odds ratio, 5.98; 95%CI, 3.7e5.4;
p < 0.001). In addition to substantial response rates and
prolonged long-term survival, nivolumab was also better
tolerated than everolimus with fewer grade 3e4 treatment-
related AEs [41]. Interestingly, neither the phase II nor
phase III studies had impressive PFS. Patients with nivolu-
mab often experienced transient progression initially after
treatment delivery [40,41]. This unconventional immune-
related response (termed pseudo-progression) has also
been demonstrated with nivolumab and ipilimumab in
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include 1) transient progression imitated by immune-cell
infiltration of the tumor and 2) lack of tumor cell death
immediately after the immune activation triggered by
nivolumab early on at the time of initial restaging scans
[40,42]. Therefore, the clinical activity of immunotherapies
should be carefully monitored.
Pembrolizumab (Keytruda, MK-3475), a humanized
monoclonal immunoglobulin G4 (IgG4) PD-1 antibody, was
initially approved by the U.S. FDA in 2014 for patients with
unresectable or metastatic melanoma and the label was
expanded to include first-line treatment in December 2015.
For patients with mRCC, pembrolizumab is still under early
phase clinical development. A phase I study of pem-
brolizumab (NCT01295827) has been conducted in order to
expand its application in more cancer types. The results
showed durable anticancer activity in multiple solid tu-
mors; however no data on RCC were reported [43]. On the
other hand, a neoadjuvant study of pembrolizumab
(NCT02212730) is underway for mRCC only. The primary
endpoints are safety and increase of intratumoral lympho-
cytic infiltration.
4. PD-1 inhibitors in mUC
Previous studies showed that PD-L1 expression increased
with advanced tumor staging, and intense PD-L1 expression
was detected in roughly 40% of specimens with carcinoma
in situ (CIS) from patients who failed BCG treatment [44].
Therefore, aberrant expression of PD-L1 in UC cells may be
predictive of aggressive disease and failure of BCG immu-
notherapy, and therapeutic blockade of PD-1/PD-L1
pathway may be effective in UC treatment [44,45]. Pem-
brolizumab targets PD-1 and has been studied in mUC. The
phase 1b KEYNOTE-012 study (NCT01848834) enrolled pa-
tients with advanced solid tumor including 33 patients with
recurrent, metastatic, or persistent UC. The preliminary
results presented at ASCO 2015 showed durable antitumor
activity in patients who responded to pembrolizumab. The
ORR to pembrolizumab was 28% (95%CI 13%e47%) including
three complete responses (CR) and five partial responses
(PR), and the response rate was higher in patients with
positive PD-L1 expression. Grade 3e4 AEs occurred in five
patients (15%), suggesting that pembrolizumab was well
tolerated in this patient cohort. Further analysis from this
study is awaited to evaluate PD-L1 as a predictive
biomarker [46]. There are several ongoing studies of pem-
brolizumab in urothelial cancer: in mUC (NCT02335424), as
neoadjuvant treatment of muscle-invasive localized UC as
monotherapy and in combination with chemotherapy
(NCT02736266 and NCT02690558), and as maintenance
therapy for mUC patients who have achieved stable disease
or better after first-line chemotherapy (NCT02500121).
4.1. PD-L1
4.1.1. Anti-PD-L1 in mRCC
Atezolizumab (Tecentriq, MPDL3280A) is an engineered
humanized lgG1 monoclonal antibody (mAb), which targets
PD-L1 and prevents binding of PD-L1 and its receptors, PD-1
and B7.1 [47]. A phase Ia study (NCT01375842) enrolled 70patients with previously treated mRCC to receive atezoli-
zumab at doses between 3 mg/kg and 20 mg/kg for up to 1
year. The results showed good tolerance with 17%
treatment-related grade 3 AEs and 4% immune-mediated
grade 3 AEs. Evaluable patients treated with atezolizu-
mab had a median PFS of 5.6 months (95%CI, 3.9e8.2
months) and median OS of 28.9 months (95%CI, 20.0 months
to not reached). Furthermore, the correlative study also
defined some potential predictive and pharmacodynamic
biomarkers may guide the studies in the future [48]. An
ongoing multicenter, phase II trial (NCT01984242) is evalu-
ating atezolizumab alone or combined with Avastin (bev-
acizumab) compared with sunitinib monotherapy in
patients with previously untreated advanced RCC. Another
ongoing phase III trial comparing the combination of ate-
zolizumab with bevacizumab against sunitinib in first-line
treatment of mRCC (NCT02420821) will be a pivotal study
in evaluating PD-L1 therapy in combination with VEGF-
targeting treatments.
BMS-936559 (MDX-1105) is a fully human IgG4 mAb that
also binds to PD-L1. A multicenter, phase I trial evaluated
its efficacy and safety in 270 patients with metastatic solid
tumors. Among 17 patients with mRCC, BMS-936559 was
administered at the dose of 10 mg/kg every 2 weeks. Two
patients in this cohort (12%) obtained an objective response
(complete or partial response) for a duration of 4 months
and 17 months, respectively. Meanwhile, an additional
seven patients (41%) experienced SD for at least 24 weeks,
and the 24-week PFS was 53% [49].
4.1.2. Anti-PD-L1 in mUC
Results from the phase Ia study (NCT01375842) mentioned
above showed noteworthy efficacy and safety of atezolizu-
mab in 67 patients with mUC. The subgroup analysis showed
that the ORRs were higher in patients with higher levels of
PD-L1 expression on tumor-infiltrating immune cells
compared with their counterparts with low expression levels
(43% vs. 11%). Atezolizumab was well-tolerated in this
population; grade 3 treatment-related AEs only occurred in
4% of patients, with no grade 4 or 5 AEs [3]. To confirm the
preliminary anti-tumor activity, a phase II, multicenter,
single-arm trial of atezolizumab was conducted in patients
with mUC progressing after platinum-based chemotherapy
(NCT02108652). Three hundred and ten patients received
the treatment with ORR of 15% (95%CI, 11%e20%,
p Z 0.005). Stratified further, patients with higher PD-L1
expression levels were more likely to derive clinical
benefit from atezolizumab, with ORR of 26%. With a median
follow-up of 11.7 months, 38 of 45 responders (84%) had
durable responses. The median PFS based on RECIST criteria
and median OS were 2.1 months and 7.9 months, respec-
tively, in the entire cohort of patients, Grade 3e4
treatment-related AEs occurred in 16% of all patients, and
any grade immune-mediated AEs occurred in 7% of patients
[50]. These results indicate that atezolizumab has disease
activity in mUC, with some patients having durable re-
sponses; moreover, atezolizumab has a favorable toxicity
profile. Based on these results, the US FDA granted accel-
erated approval of atezolizumab for use in cisplatin-
refractory bladder cancer on May 18, 2016. An ongoing
phase III study will compare outcomes from atezolizumab
monotherapy and chemotherapy (either paclitaxel or
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refractory mUC (NCT02302807; IMvigor211).
There are two other IgG1 mAb targeting PD-L1
(MED14736 (durvalumab) and MSB0010718C) currently un-
dergoing early phase studies in various solid tumors. No
data for RCC or UC cohorts are yet available [51,52].
5. PD-L1 expression
A great challenge of tumor immunotherapy is to identify a
specific biomarker for patient selection and disease man-
agement. Increased PD-L1 expression on tumor cells is
likely driven by constitutive oncogenic pathways, and
recent research also indicates that PD-L1 may have dual
roles both to suppress the immune response and also to
induce endogenous inflammatory immune responses. The
final outcome is determined by the balance of the host
immune response and negative feedback modulation [53].
Preclinical and translational studies have demonstrated
that high PD-L1 expression levels in tumors are associated
with aggressive disease and poor prognosis in various types
of cancer including RCC and UC [44,45,54]. This is also the
basis of therapeutic blockade of PD-1/PD-L1 pathway.
However, whether the PD-L1 expression can predict clinical
efficacy of PD-1/PD-L1 inhibitors is still controversial and
depends on tumor types. An association of tumor PD-L1
expression level and clinical efficacy of nivolumab has
been detected in metastatic melanoma and non-squamous
cell non-small cell lung cancer [55,56]. When exploring in
other cancer types, two phase I trials of nivolumab in
various solid tumors showed that 75% and 36% of PD-L1
positive patients, respectively, responded to the study
drug while none of the PD-L1 negative patients did [37,38]
in the phase II study of mRCC, nivolumab showed a higher
response rate (31%) in patients with PD-L1 positive disease
compared to 18% in patients with PD-L1 negative disease
[40]. However, in the phase III RCC study, there was no
correlation between PD-L1 status and response to nivolu-
mab. Similarly, a phase Ia study of atezolizumab demon-
strated that anti-PD-L1 therapy was effective in both PD-L1
positive and negative patients with solid tumors, including
RCC and UC, although the response rate was lower in PD-L1
negative group (ORR, 39% vs. 13%) [57].
Based on the results above, PD-L1 expression in tumor
cells likely cannot be used as the sole biomarker to predict
for treatment responses to PD-1/PD-L1 inhibitors; this
inability to accurately serve as a predictive biomarker may
be due to several reasons. First, PD-L1 expression is a dy-
namic parameter that may change over time, and many
clinical trials use archival tissue to evaluate for PD-L1
positivity. PD-L1 expression has been found to be discor-
dant between primary tumors and metastatic lesions, as
well as between metastatic lesions from the same patient
[18,58]. Secondly, there is no technical standard for PD-L1
detection with different thresholds of defining PD-L1 posi-
tivity (tumor cells showed membranous staining on immu-
nohistochemistry of 5% or 1%), specimen collection
(archival or fresh tumor samples) and antibodies for IHC
testing (murine or rabbit) [37,38,40,41,49,57]. Recent
studies have demonstrated that it might be the high level of
PD-L1 expression on tumor-infiltrating immune cells ratherthan tumor cells that are associated with higher response
rates and improved OS [3,50]. Despite this controversy, one
of the PD-L1 biomarker tests (the Ventana PD-L1 assay) has
been approved by the US FDA as a companion diagnostic for
PD-L1 positivity in mUC patients undergoing treatment with
atezolizumab [3,50,59,60]. Finally, gene mutations may
accumulate over time to create neoantigens that can be
recognized by cytotoxic T-cells performing immune sur-
veillance. Indeed, molecular subtypes of UC identified by
The Cancer Genome Atlas (TCGA) analysis are associated
with different levels of CD8þ (cytotoxic T-cell) effector
genes as well as PD-L1 expression on immune cells or tumor
cells. These difference scan also be a factor in determining
patient responses to the immune checkpoint inhibitors [50].
Due to the dynamic feature of the host immune response
to tumors and comprehensive regulation by multiple im-
mune checkpoints, it may be difficult to identify treatment
candidates and make disease management decisions with a
single biomarker. Further studies on the tumor microenvi-
ronment may help us distinguish between an immunogenic
tumor microenvironment and a non-immunogenic tumor
microenvironment [18].
6. Combination immune therapy
Immune checkpoint inhibitors combined with other immu-
notherapy or conventional treatment are the development
direction of the future. PD-1 and CTLA-4 play complemen-
tary roles to down-regulate adaptive immunity. Preclinical
studies have demonstrated that combined blockade of PD-1
and CTLA-4 may induce non-redundant antitumor activity
compared with monotherapy of each [61e63]. Therefore, a
phase I trial of advanced melanoma (NCT01024231) was
conducted. The results revealed that concurrent therapy
with ipilimumab and nivolumab was well tolerated and
provided distinct clinical activity compared with published
data on monotherapy with either agent alone. Interestingly,
there was no significant difference of ORR between PD-L1
positive and PD-L1 negative tumors [42]. The preliminary
results of an ongoing phase I trial showed similar results of
this combination in patients with mRCC [64]. The phase III
study of first-line ipilimumab and nivolumab compared to
sunitinib monotherapy in mRCC (NCT02231749) has
completed accrual, and clinical results are pending. A
separate phase III trial is currently randomizing patients with
previously untreated bladder cancer to either the combina-
tion of tremelimumab-durvalumab or chemotherapy (gem-
citabine with either carboplatin or cisplatin) (NCT02516241).
Conventional therapeutic strategies may also have syn-
ergistic functions with checkpoint inhibitors by inducing
tumor cell death and releasing tumor-related antigens to
initiate T-cell activation. The synergistic anti-tumor effect
of dual blockade of VEGFR2 and PD-1 was detected in a
murine colon cancer model, and there was no increased
toxicity [65]. Preliminary analysis from a phase I trial of
mRCC also demonstrated encouraging efficacy and
manageable toxicity of nivolumab plus sunitinib or pazo-
panib [66]. Many other clinical trials are underway to
evaluate the combination of immune checkpoint inhibitors
with other targeted therapy or chemotherapy. Table 1 lists
a series of ongoing trials in RCC and UC.
Table 1 Summary of ongoing clinical trials with immune checkpoint inhibitors combined with other therapies in RCC or UC.
Identifier Phase Cohort Combinations Primary endpoints Estimated
enrollment
NCT02210117 Pilot RCC Nivolumab vs. nivolumab þ bevacizumab vs.
nivolumab þ ipilimumab
Safety and tolerability 60
NCT02133742 Ⅰ RCC Pembrolizumab þ axitinib DLT 60
NCT02348008 Ⅰ,Ⅱ RCC Pembrolizumab þ bevacizumab DLT 61
NCT02599779 Ⅱ RCC Pembrolizumab þ SBRT PFS 35
NCT02724878 Ⅱ Non-clear
cell RCC
Atezolizumab þ bevacizumab ORR 40
NCT02420821 Ⅲ RCC Atezolizumab þ bevacizumab vs. sunitinib PFS and OS 830
NCT01441765 Ⅱ RCC CT-011 vs. CT-011 with DC/RCC fusion vaccine Toxicity and response
rate
44
NCT02437370 Ⅰ UC Pembrolizumab þ docetaxel vs. pembrolizumab þ
gemcitabine
Safety and tolerability 38
NCT01524991 Ⅱ UC Gemcitabine, cisplatin þ ipilimumab 1-year OS 36
NCT02619253 Ⅰ,Ⅱ RCC and UC Pembrolizumab þ vorinostat MTD 42
NCT02496208 Ⅰ RCC, UC Nivolumab þ cabozantinib vs. nivolumab þ
cabozantinib þ ipilimumab
DLT 66
DLT, dose limited toxicity; MTD, maximum tolerated dose; ORR, overall response rate; OS, overall survival; PFS, progression free
survival; RCC, renal cell carcinoma; UC, urothelial carcinoma.
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The therapies and checkpoint targets described above are
farthest along in clinical development. Nevertheless, there
are other immune checkpoint molecules which have been
identified in basic studies or have already moved forward
into clinical investigation.
Lymphocyte-activation gene-3 (LAG-3; also known as
CD223) is highly expressed on regulatory T-cells (Treg) to
amplify the immunosuppressive function of Treg cells but
also to inhibit CD8þ effector T-cell activity [67,68]. The
only known ligands for LAG-3 are MHC class II molecules,
which are highly expressed on some epithelial cancers and
tumor-infiltrating APCs. Since LAG-3 and PD-1 are typically
co-expressed on anergic or exhausted T-cells, dual
blockade of these two receptors may cause a synergistic
reversal of tumor-specific immunosuppression. Impressive
evidence from a preclinical murine study showed that
Pd1/Lag3/double-knockout mice completely reject
even poorly immunogenic tumors but rapidly develop se-
vere autoimmune syndromes [69]. Hence, the balance be-
tween antitumor effects and autoimmunity should be
carefully considered in such combination strategies.
Recently, anti-LAG-3 agents have moved forward into
clinical development to evaluate the safety and efficacy of
anti-LAG-3 as either a monotherapy or in combination with
anti-PD-1 agents (NCT01968109 and NCT02460224).
In addition to LAG-3, many other molecules involved in
antitumor immunity may become potential target for can-
cer treatment, such as T-cell immunoglobulin and mucin-
domain containing-3 (TIM-3; also known as HAVcr2), B and T
lymphocyte attenuator (BLTA; also known as CD273) and
adenosine A2a receptor (A2aR). All of these “second gen-
eration” inhibitory receptors are under basic or preclinical
investigation [17,22].
On the other hand, limited studies focus on using
agonist antibodies to promote immunoactivation. CD27 isan activating transmembrane receptor expressed on not
only naive and activated T cells, but also memory B cells
and a subset of NK cells [70]. The therapeutic potential of
CD27 was fist revealed in a study investigating the anti-
tumor effect of an anti-CD40 agonist. With a CD70 mAb
blocking the CD70/CD27 pathway, the antitumor activity of
the anti-CD40 mAb was totally abolished, indicating the
importance of CD27 in promoting antitumor immunity [71].
Activating the CD27 receptor is therefore a novel approach
to increasing cytotoxic T-cell responses. 1F5 (varlilumab)
was the first fully humanized antibody to recognize and
stimulate CD27-expressing T cells, increasing the number of
antigen-specific CD8þ T cells with potent antitumor activity
[72]. Varlilumab has now entered clinical investigation.
There are several ongoing phase I/II studies combining
varlilumab and PD-1/PD-L1 blockade (nivolumab and ate-
zolizumab, respectively) accruing advanced solid tumors
(NCT02335918 and NCT02543645). Both of these studies will
have a planned phase II dose expansion cohort of mRCC
patients. There is also another phase I/II study specifically
recruiting patients with mRCC to investigate the combina-
tion of varlilumab and sunitinib, thus combining immune
activation with an anti-angiogenesis agent (NCT02386111).
As more targetable immune checkpoint targets are
identified, future combination approaches are essential to
improve upon the current response rates seen with immune
checkpoint monotherapies.
8. Summary
The landscape of immune checkpoint inhibitors has rapidly
expanded in the past 5 years. With immense interest from
the medical community in immunogenic cancers such as
urothelial and renal cell carcinomas, great advances in
immunotherapy have culminated in the approval of atezo-
lizumab for urothelial cancer and nivolumab for RCC.
However, PD-L1 status is not a reliable predictive biomarker
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find clinical characteristics of sensitivity or resistance to
these immunotherapies. Clinical response rates to immu-
notherapy in the treatment-refractory setting remain poor,
and prospective studies are needed for both combination
immune therapy strategies as well as for combinations of
immune and cytotoxic therapies. Several studies are
currently evaluating immunotherapies in first-line therapy
for metastatic disease in both mRCC and mUC. Finally,
since these agents are beneficial in the metastatic setting,
it is important to evaluate their utility for patients with
localized disease. Ongoing research is evaluating the use of
immune checkpoint therapies in earlier disease states such
as adjuvant therapy to prevent metastases after definitive
local treatments, as well as neoadjuvant therapy to
improve local disease control.Conflicts of interest
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